A Phase III trial of Sanofi’s isatuximab’s has proven successful, showing that the drug achieved the primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma.
News
Boots to launch specialist pharmacist practitioner role
Boots UK has announced plans to introduce a new specialist pharmacist practitioner role.
Polypharmacy reviews becoming ‘increasingly important’
The Royal Pharmaceutical Society (RPS) has published guidance on polypharmacy for pharmacists and all healthcare organisations involved with medicines.
Mapping of oesophageal cancer gene mutations leads to new drug targets
Mutations that cause oesophageal adenocarcinoma (OAC) have been mapped in unprecedented detail, unveiling good news that more than half could be targeted by drugs currently already in trials for other cancer types.
FDA rejects Alkermes’ depressive disorder drug
The US Food and Drug Administration (FDA) has rejected Alkermes’ filing for ALKS 5461 in major depressive disorder (MDD), asking for more clinical data.
Migraine treatment Ajovy among CHMP’s six endorsed medicines
Six medicines have taken a giant leap toward winning approval in Europe having won the backing of the European Medicines Agency’s (EMA) human medicines committee (CHMP).
Forxiga receives positive EU CHMP for type I diabetes in adults
AstraZeneca’s Forxiga has been recommended by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) as an oral adjunct treatment to insulin in adults with type I diabetes.
CHMP recommends EU approval of Roche’s Tecentriq
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Roche’s Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer.
New Primary Care Network model to create 100,000 extra appointments
GP practices in Gloucestershire are currently working together to provide 100,000 more appointments for patients.
Havas Lynx comes out on top at 2018 PM Society Awards
Havas Lynx stacked up an impressive eight Gold awards at the 33rd annual PM Society Awards in London on Friday, for exceptional work within the healthcare advertising and communications landscape.
Fantastic response for International Clinical Researcher of the Year 2019
Following its path as one of the most prestigious awards of its kind, this year’s PharmaTimes International Clinical Researcher of the Year competition has seen an incredible increase in entries and passes of more than 50% from 2018, and a 37% increase in essays submitted. It’s a good job we have such incredible, dedicated judges, with over 100 essays submitted in one category alone!
The benefits of entering Clinical Researcher of the Year – as told by past winners
Whether you’re a Clinical Research Associate, a Project Manager, part of a Strategic team or work in another field, there’s a category for you in this year’s Clinical Researcher of the Year – The Americas.
Novartis spend on digital and data ‘in the 100s of millions’
In its annual results briefing in Basel, Switzerland, Novartis emphasised the integration of digital and data into the way the company works, claiming to be spending ‘in the 100s of millions’ on collating its ‘goldmine’ of more than two million patient years of clinical trial data.
Kymriah gets NICE approval for DLBCL
The National Institute for Health and Care Excellence (NICE) has approved Novartis’ chimeric antigen receptor T-cell (CAR T-cell) therapy Kymriah for treatment of adults with diffuse large B-cell lymphoma (DLBCL).
Male contraception being tested in Manchester and Edinburgh
Male contraception is being put to the test in Manchester and Edinburgh, where couples are being invited to take part in a ground-breaking international study trialling a new form of male contraception.
